Vivitrol 380mg
Drug
Alkermes, Inc.
Total Payments
$7.8M
Transactions
6,868
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $1.7M | 14 | 0 |
| 2017 | $6.1M | 6,854 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.8M | 6,868 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Naltrexone for use in Conjunction with Buprenorphine in Adults with Opioid Use Disorder Transitioning from Buprenorphine Maintenance Prior to First Dose of VIVITROL ( r) | Alkermes, Inc. | $2.6M | 0 |
| A Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Low Dose Naltrexone for use in Conjunction with Buprenorphine in Adults with Opioid Use Disorder Prior to First Dose of VIVITROL | Alkermes, Inc. | $2.0M | 0 |
| Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder | Alkermes, Inc. | $1.2M | 0 |
| Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up | Alkermes, Inc. | $289,289 | 0 |
| Improving Outcomes of Opioid Addicted Prisoners with Extended Release Injectabel Naltrexone before Reentry | Alkermes, Inc. | $278,817 | 0 |
| Novel interventions for alcohol dependent frequent ED users | Alkermes, Inc. | $236,929 | 0 |
| Alcohol Dependence Hopsital Treatment (ADOPT) Study | Alkermes, Inc. | $229,075 | 0 |
| Injectable Pharmacotherapies for Opioid Use Disorders (IPOD) | Alkermes, Inc. | $179,333 | 0 |
| Opioid Relapse and HIV Risk: 48 vs. 24 Weeks of Injectable Extended Release Naltrexone | Alkermes, Inc. | $168,861 | 0 |
| Predictors of Early Treatment Response to Extended-Release Naltrexone (XR-NTX) for Opioid Use Disorder | Alkermes, Inc. | $129,507 | 0 |
| Extended Release Naltrexone Opioid Treatment at jail to community re-entry | Alkermes, Inc. | $108,647 | 0 |
| Opioid Relapse & HIV Risk: 48 vs. 24 Weeks of Injectable Extended Release Naltrexone | Alkermes, Inc. | $85,085 | 0 |
| Buprenorphine Stabilization and Induction onto VIVITROL for Heroin-Dependent Individuals | Alkermes, Inc. | $80,479 | 0 |
| Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Combining HCV and Addiction Treatment of Young Suburban Heroin Users (SHU) That Addresses Barriers to Care | Alkermes, Inc. | $65,156 | 0 |
| Harm reduction with Pharmacology (HARP) for homeless people with alcohol use disorders | Alkermes, Inc. | $45,815 | 0 |
| Integrated Collaborative Care for Substance use Disorders | Alkermes, Inc. | $44,506 | 0 |
| Predicators of Early Treatment Response to Extended-Release Naltrexone for Opioid Use Disorder | Alkermes, Inc. | $25,901 | 0 |
| A Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Naltrexone for use in Conjunction with Buprenorphine in Adults with Opioid Use Disorder Transitioning from Buprenorphine Maintenance Prior to First Dose of VIVITROL | Alkermes, Inc. | $19,264 | 0 |
| Long-acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification with Naltrexone vs. Buprenorphine | Alkermes, Inc. | $13,090 | 0 |
| A Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Low Dose Naltrexone for use in Conjunction with Buprenorphine in Adults with Opioid Use Disorder Prior to First Dose of VIVITROL (r ) | Alkermes, Inc. | $569.70 | 0 |
Top Doctors Receiving Payments for Vivitrol 380mg
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Menands, NY | $7.8M | 6,868 |
Ad
Manufacturing Companies
- Alkermes, Inc. $7.8M
Product Information
- Type Drug
- Total Payments $7.8M
- Total Doctors 0
- Transactions 6,868
About Vivitrol 380mg
Vivitrol 380mg is a drug associated with $7.8M in payments to 0 healthcare providers, recorded across 6,868 transactions in the CMS Open Payments database. The primary manufacturer is Alkermes, Inc..
Payment data is available from 2017 to 2018. In 2018, $1.7M was paid across 14 transactions to 0 doctors.
The most common payment nature for Vivitrol 380mg is "Unspecified" ($7.8M, 100.0% of total).
Vivitrol 380mg is associated with 20 research studies, including "A Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Naltrexone for use in Conjunction with Buprenorphine in Adults with Opioid Use Disorder Transitioning from Buprenorphine Maintenance Prior to First Dose of VIVITROL ( r)" ($2.6M).